Neuroprotective effect of hydroxypropyl-β-cyclodextrin in hypoxia-ischemia

Abstract

Neonatal cerebral ischemic injury is a common and debilitating pathology for which there is currently no known purely pharmacological treatments that are effective when delivered immediately after injury. Cyclodextrins are cyclic oligosaccharides that can remove cholesterol from cell membranes and thereby affect receptor function. Cyclodextrins have previously been shown to be neuroprotective in vitro. We showed that hydroxypropyl-β-cyclodextrin is neuroprotective in rats in vivo when delivered by intraperitoneal injection 30 min following hypoxia-ischemia, when assessed 15 days after surgery. A single dose of 1 g/kg hydroxypropyl-β-cyclodextrin reduced brain infarction size by 28.57% compared with control (P<0.001). We also report that the same compound reduces neuronal excitability in hippocampal slices and propose that hydroxypropyl-β-cyclodextrin is neuroprotective by reducing excitotoxicity in the delayed phase of brain damage.

Ratlarda Sugammadex ve Rocuronium Kombinasyonunun Kraniyal Nörotoksisite Üzerine Etkisi: Deneysel Çalışma

“…Neuroprotective effects have been demonstrated in studies with methyl-β-cyclodextrin and 2-hydroxypropylb-cyclodextrin [17][18][19] . A recently study was determined that sugammadex had a neuroprotective effect against transient cerebral ischemia.…”

Effectiveness of sugammadex for cerebral ischemia/reperfusion injury

“…In experimental studies, HP‐CD is used as a carrier for lipophilic medications and as an odor remover [35]. Other lipophilic medication carriers such as ethanol and dimethylsulfide have neuroprotective characteristics [36,37]. Frank et al.…”

“…Many cyclodextrin groups protect cortical neurons, cultured without normal calcium signal effect, against glutamate excitotoxicity and NMDA and oxygen-glucose deprivation [36]. Methyl-b-cyclodextrin has been found to protect the hippocampal areas from the effects of anoxia [37]. Abulrob et al [5] studied the cyclodextrin 2hydroxypropyl-b-cyclodextrin (HP-CD) and showed that it had neuroprotective features.…”

“…In experimental studies, HP-CD is used as a carrier for lipophilic medications and as an odor remover [35]. Other lipophilic medication carriers such as ethanol and dimethylsulfide have neuroprotective characteristics [36,37]. Frank et al [6] reported that, as with other b-cyclodextrins, methyl-b-cyclodextrin reduced neuronal excitability in the hippocampal area as methyl-b-cyclodextrin treatment can separate cholesterol in the postsynaptic area, causing disruption of NMDA and a-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid receptorlinked glutamate transmission.…”

Supramolecular Pharmaceutical Sciences: A Novel Concept Combining Pharmaceutical Sciences and Supramolecular Chemistry with a Focus on Cyclodextrin-Based Supermolecules

“…Recently, various bioactivities of CyDs have been demonstrated, and CyDs have been used as active pharmaceutical ingredients (APIs) against Niemann-Pick disease type C (NPC), [62][63][64][65][66][67][68][69][70][71][72][73][74][75][76] leukemia, 77) hyperlipidemia, 78) Alzheimer's disease, [79][80][81][82][83][84] cerebral ischemic injury, 85) atherosclerosis, 86) diabetic kidney disease, 87) chronic renal failure, 88) AIDS, 89,90) influenza, 91) peripheral artery disease, 92) sterility, [93][94][95] solid cancers, [96][97][98][99][100][101] bacterial growth, 102) α-synucleinopathy, 103) GM1-gangliosidosis, 104) septic shock, [105][106][107] hypervitaminosis, 108) and transthyretin-related familial amyloidotic polyneuropathy (FAP) …”